Home
News
Create
Screeners
Insights
Jenburkt Pharmaceuticals
1,051.
00
-9.00
(-0.85%)
Market Cap
₹463.83 Cr
PE Ratio
14.43
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.85%
1M
+9.71%
6M
-2.79%
1Y
-3.49%
5Y
+133.74%
View Company Insights
Latest news about Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals confirms 'not a large corporate' status for FY26
Apr 14, 2026
Jenburkt Pharmaceuticals Limited disclosed to BSE Limited on April 14, 2026, that it maintains 'not a large corporate' status for FY ended March 31, 2026. The disclosure complies with SEBI Circular SEBI/HO/DDHS/CIR/2021/613, confirming the company does not meet large corporate criteria under Clause 2.1 of Chapter XII. The communication was jointly authorized by Whole Time Director & CFO Dilip H. Bhuta and Sr. Vice President & Company Secretary Ashish R. Shah.
Jenburkt Pharmaceuticals Files Quarterly Compliance Certificate for Q4 FY26
Apr 07, 2026
Jenburkt Pharmaceuticals Reports Q3FY26 Results with Revenue of Rs 4302.39 Lacs
Feb 03, 2026
Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026
Oct 28, 2025
Jenburkt Pharmaceuticals Reports Strong Q4 Results, Announces Dividend
May 20, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO